FMP
NASDAQ
3.03 USD
-0.15 (-4.95%)
Dr. Wei-Wu He Ph.D.
Healthcare
Biotechnology
https://www.casipharmaceuticals.com
NASDAQ
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Pha...
0000895051
US14757U2087
14757U208
9620 Medical Center Drive
240 864 2600
US
224
Jun 12, 1996
0000895051
NASDAQ
Biotechnology
Healthcare
14757U208
US14757U2087
US
3.03
0.39
206.8k
40.36M
-
1.6-8.48
2.22
-
-
-
-
-1.01
-
https://www.casipharmaceuticals.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.